Your session is about to expire
← Back to Search
Monoclonal Antibodies
LY3462817 - Subcutaneous (SC) for Psoriasis
Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through final follow-up (up to week 52 for ly3462817 & up to week 16 for ly3509754)
Summary
This trial is testing two new drugs, LY3462817 and LY3509754, to see if they are safe for people with psoriasis. Researchers will observe how the body processes these drugs. The study will last over a year for LY3462817 and a few months for LY3509754.
Eligible Conditions
- Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through final follow-up (up to week 52 for ly3462817 & up to week 16 for ly3509754)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through final follow-up (up to week 52 for ly3462817 & up to week 16 for ly3509754)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to LY3462817 and LY3509754
Secondary study objectives
Pharmacokinetics (PK): Average Concentration (Cave) of LY3462817 and LY3509754
Trial Design
6Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3509754Experimental Treatment1 Intervention
LY3509754 administered orally.
Group II: LY3462817 - Subcutaneous (SC)Experimental Treatment1 Intervention
LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
Group III: LY3462817 - Intravenous (IV)Experimental Treatment1 Intervention
LY3462817 administered as IV infusions.
Group IV: Placebo - SCPlacebo Group1 Intervention
Placebo administered as SC injections. (SC administration is discretionary/optional.)
Group V: Placebo - IVPlacebo Group1 Intervention
Placebo administered as IV infusions.
Group VI: PlaceboPlacebo Group1 Intervention
Placebo administered orally.
Find a Location
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,671 Previous Clinical Trials
3,228,992 Total Patients Enrolled
37 Trials studying Psoriasis
20,623 Patients Enrolled for Psoriasis
Study DirectorEli Lilly and Company
1,386 Previous Clinical Trials
426,617 Total Patients Enrolled
31 Trials studying Psoriasis
10,506 Patients Enrolled for Psoriasis
Share this study with friends
Copy Link
Messenger